Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines aimed at correcting abnormal gene expression to treat serious diseases, with an initial emphasis on oncology [1][3] Company Participation in Events - Management will participate in several key industry events, including the Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025, and Goldman Sachs 46th Annual Global Healthcare Conference 2025 [1][2] - A webcast of the presentations will be available for 30 days on the company's website [2] Company Overview - Foghorn Therapeutics is developing its proprietary Gene Traffic Control® platform to identify and validate drug targets within the chromatin regulatory system, focusing on genetically determined dependencies [3] - The company is advancing multiple product candidates specifically in the oncology sector [3]